Frazis Capital Podcast

Mike and Ellianna discuss

Mike and Ellianna discuss the latest market moves.Sections00:00 - US Tariffs and Market Reactions06:35 - Managing Risk12:41 - Opportunities in Tech and Healthcare21:18 - Reddit23:54 - Market Dynamics and Short Selling28:54 - Clarity's Market Position and Future Prospects33:43 - Biotech Sector Valuation and Mispricing35:55 - Interest Rates and Economic Implications39:50 - Future Investment Strategies and Growth Opportunities

00:00 - Introduction to Radiopharmaceuticals and PSMA03:00 - Current State of PSMA in Prostate Cancer Treatment06:04 - Comparative Analysis: US vs Australia in Radiopharmaceuticals09:02 - Imaging Techniques and Their Impact on Diagnosis12:14 - The Patient Journey: From Diagnosis to Treatment14:56 - Challenges in Sensitivity and Specificity of Imaging17:57 - Post-Treatment Monitoring and Biochemical Recurrence21:09 - Innovations in Radiopharmaceuticals and Future Directions23:57 - Market Dynamics and Regulatory Challenges26:56 - Conclusion and Future of Prostate Cancer Imaging36:05 - Advancements in Targeted Therapies for Prostate Cancer41:12 - The Future of Combination Therapy42:52 - Imaging Innovations in Cancer Detection44:45 - Challenges in Treatment Approval and Reimbursement51:46 - The Role of Multiple Targets in Cancer Therapy54:40 - Exploring New Agents and Their Applications01:00:14 - The Need for Improved Reimbursement Pathways

00:0 True Customer Love and Explosive Growth02:05 - Portfolio update04:09 - Hims: A Case Study in True Customer Love and Explosive Growth07:18 - Defining True Customer Love11:33 - The Future of Hims and Market Dynamics in GLP-1sClarity's Fast-Tracked Approval and Market Response27:06 - Short Selling in CU629:59 - If you want to be valued like a US biotech company, you have to be capitalized like one32:10 - Clarity's FDA trial timeline36:33 - Updates from Nubank and MercadoLibre 40:54 - Customer Love and Explosive Growth44:45 - Identifying Explosive Growth Opportunities52:02 - Influence of Tech Leaders on Market Trends59:30 - Long-Term Perspectives on Semiconductor Growth

Timestamps 00:00 - The Rise of DeepSeek: A Game Changer in AI 02:52 - Impact on Valuations and Capital Expenditure 05:55 - Investment Strategies in 2025 08:52 - Focus on Australian Biotech and Healthcare Takeaways DeepSeek's AI system is a major disruptor in the market. The release of model weights challenges existing AI business models. Investors are reconsidering large investments in foundational models. Apple and AWS may benefit from the efficiency of DeepSeek's model. Semiconductor investments are highly cyclical and risky. Startups may struggle to secure funding in a downturn. Australian biotech presents interesting investment opportunities. Clarity Pharmaceuticals is a notable player in the biotech space. The Australian market is underperforming compared to Wall Street. Government hiring is impacting the private sector's performance. titles DeepSeek, AI, investment, market impact, semiconductor, Australian biotech, valuations, data centers, technology, healthcare

Paul Anderson, CEO of Orthocell, discusses the company's collagen-based medical devices aimed at regenerative medicine. He covers their products for bone regeneration, nerve repair, and tendon repair, highlighting their clinical success and market potential. The conversation also covers the company's strategic partnerships, regulatory approvals, and future plans for expansion, particularly in the U.S. market. Paul emphasizes the company's commitment to manufacturing in Australia. Takeaways - Orthocell specializes in regenerative medicine with a focus on collagen-based products. - The company has developed three main products for bone, nerve, and tendon repair. - Their bone regeneration product is approved in multiple jurisdictions, including the U.S. and Europe. - The nerve repair product aims to improve surgical outcomes by reducing scar tissue. - Clinical trials have shown an 85% success rate in nerve repair surgeries. - The market for their products is estimated to be worth $3.5 billion globally. - Orthocell plans to enter the U.S. market with a 510(k) submission by the end of 2024. - The company has raised $17 million to support its U.S. expansion efforts. - Their manufacturing process is based in Australia, emphasizing local production. - The leadership team includes experienced professionals with strong industry connections. Chapters 00:14 - Overview of Orthocell and Its Products 03:51 - Bone Regeneration Product and Market Potential 06:28 - Nerve Repair Product: Innovation and Benefits 13:44 - Clinical Outcomes and Patient Impact 19:02 - Market Competition and Future Directions 24:13 - Entering the US Market 25:32 - Regulatory Pathways and Approvals 27:14 - Marketing Strategies and Clinical Data 29:50 - Product Differentiation and Competitive Edge 32:05 - Market Sizing and Revenue Potential 34:59 - Pricing Strategy and Economic Benefits 38:18 - Sales Distribution and Partnerships 39:32 - Financial Position and Board Strength 42:41 -Future Milestones and Expectations Keywords Orthocell, regenerative medicine, collagen, nerve repair, medical devices, clinical trials, market strategy, healthcare innovation, product launch, financial growth